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Randomized Placebo-Controlled Trial of
Outpatient (at Home) Cervical Ripening
With Isosorbide Mononitrate (IMN) Prior to
Induction of Labor—Clinical Trial With
Analyses of Efficacy and Acceptability:
The IMOP Study
S. S. Bollapragada, F. MacKenzie, J. D. Norrie, O. Eddama, S. Petrou,
M. Reid, and J. E. Norman
Division of Developmental Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom;
Health Services Research Unit, Centre for Healthcare Randomised Trials (CHaRT), Aberdeen University,
Aberdeen, United Kingdom; National Perinatal Epidemiology Unit, University of Oxford, Oxford,
United Kingdom; and Division of Community Based Sciences, University of Glasgow, Glasgow, United Kingdom
BJOG 2009;116:1185–1195
ABSTRACT
Several investigators have hypothesized that outpatient preinduction cervical ripening with nitric oxide donors such as
isosorbide mononitrate (IMN) would reduce the elapsed time from hospital admission to delivery and improve women’s
experience of induction of labor. This double-blind randomized placebo-controlled trial investigated whether vaginal
self-administration at home by woman at term would improve the process of induction of labor. The study subjects were 350
nulliparous singleton women with cephalic presentation at 37 weeks’ gestation, requiring cervical ripening before induction of
labor. The participants self-administered IMN (n 177) or placebo (n 173) vaginally at home without fetal monitoring at 48, 32,
and 16 hours before the scheduled time of admission for induction of labor. The primary study outcome measures were the elapsed
time interval from hospital admission to delivery and the women’s experience of home treatment for cervical ripening. Maternal
satisfaction was determined with a questionnaire, using a 10 point scale with 1  extremely good and 10  not at all good.
There was no statistically significant difference between the 2 study groups in the admission to delivery interval; the
mean difference was 1.59 hours, with a 95% confidence interval (CI) of5.08 to 1.89, P 0.37. Compared to placebo,
however, IMN was more effective in inducing a mean change in modified Bishop score from recruitment to hospital
admission (mean difference: 0.65 [95% CI, 0.14–1.17, P  0.013]). With regard to maternal satisfaction, the overall
experience of home treatment was positive in both groups. Women in the placebo group reported it to be marginally
more positive than those in the IMN group (placebo: 3.23 vs. IMN: 3.84; the mean difference was 0.61, with a 95% CI
of 0.02–1.21, P  0.043). No difference between the 2 groups was reported in either pain or anxiety levels or in the
willingness to have the treatment in a subsequent pregnancy.
These data show that administration of IMN at home is effective in ripening the cervix but does not shorten the
admission to delivery interval or improve maternal satisfaction. The investigators conclude from these findings that IMN
in this setting has limited clinical value.
EDITORIAL COMMENT
(The appeal of the nitric oxide donor isosor-
bide mononitate (IMN) is its potential to induce
cervical ripening without precipitating uterine
contractions and thereby obviate the need for
fetal heart rate monitoring, and allow cervical
ripening to be conducted on an outpatient ba-
OBSTETRICSVolume 64, Number 11OBSTETRICAL AND GYNECOLOGICAL SURVEYCopyright © 2009 by Lippincott Williams & Wilkins
www.obgynsurvey.com | 699
sis. Its utility for this purpose has been evalu-
ated in 3 randomized trials.
In the first, 200 women at 42 weeks’ gestation
or beyond with an uncomplicated singleton
pregnancy were randomly allocated to 40 mg of
vaginal IMN or placebo inserted into the poste-
rior vaginal fornix by an obstetrician the day
before induction. The primary outcome was en-
try into spontaneous labor before the scheduled
induction. Significantly more women in the IMN
group achieved this outcome, 22% versus 8%.
In the women who did not enter labor sponta-
neously, IMN was no more effective at improv-
ing the Bishop score than placebo. Overall,
there were no significant differences between
groups in mode of delivery, maternal bleeding
complications, or infant condition at birth. There
were no cases of abnormal fetal heart rate in the
IMN group before the active phase of labor but
many more women in the IMN group experi-
enced headache, 88% versus 8% (Bullarbo M,
et al. Am J Obstet Gynecol 2007;196:50e1).
In the second trial, 102 women were random-
ized to self-administration of 3 vaginal doses of
40 mg of IMN or placebo 36, 24, and 12 hours
before scheduled induction. The primary out-
come in this trial was time interval from hospital
admission until delivery. This interval was signif-
icantly shorter in the IMN group, 13 versus 20
hours. The Bishop score from randomization
was increased from 4 to 6 in the IMN group, but
it was not increased in the placebo group. There
was no difference between groups in the rate of
spontaneous labor—8% in the IMN group and
6% in the placebo group. Fewer women in the
IMN group received prostaglandins for cervical
ripening, 63% versus 90%. Tachysystole, defined
as two 10-minute windows with more than 5 con-
tractions, was less frequent in the IMN group, 2%
versus 16%. As in the Bullarbo trial, there were no
significant differences between groups in mode of
delivery, maternal bleeding complications, or in-
fant condition at birth. Headache was less fre-
quent than in the Bullarbo trial, and occurred
exclusively in the IMN group, in which the rate was
12% (Habib S, et al. IJOG 2008;101:57).
The abstracted trial of Bollapragada et al is the
largest trial yet to evaluate outpatient cervical rip-
ening with IMN. In this trial, a self-administered,
3-dose, 40-mg vaginal IMN regimen had no
meaningful clinical effect, even though it did im-
prove the Bishop score by an average of 0.65
relative to placebo. IMN was not associated with
maternal or perinatal harm, but again, caused
more headaches, 66% versus 20%.
On the basis of these 3 trials, it is hard to get
enthusiastic about the use of IMN for outpatient
cervical ripening. The issue may be worthy of future
study, but for now I am going to spare my patients
the headache(s) of this intervention.—DJR)
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ABSTRACT
This investigation was conducted as part of the Mother-Infant Rapid Intervention at Delivery (MIRIAD) study,
a prospective, multicenter trial assessing routine rapid human immunodeficiency virus (HIV) screening of pregnant
women in inpatient and outpatient settings. This study compared rapid HIV testing with conventional HIV testing
in outpatient obstetric settings among a population of pregnant women who presented late in care with undocu-
mented HIV status. The investigators hypothesized that rapid testing would provide results faster than conventional
testing in this setting and would also be acceptable and feasible. The study was carried out in 285 nonlaboring
pregnant women volunteers at 34 weeks’ gestation, who presented at hospital clinics in 6 US cities between 2002
and 2005. Median times between conventional and rapid testing and between rapid point-of-care and rapid
laboratory-based testing were determined. More than 90% of eligible women who were approached agreed to
participate.
Results were available for rapid tests much sooner than for conventional tests: median time between blood draw
and availability of results was 25 minutes (range, 20–110 minutes) among women with rapid HIV testing and 23
hours (range, 3.5 hours–43 days) among women with conventional testing (P  0.0001). Most results for rapid
testing (n  273 or 96%) were available within 1 hour. Median test duration was shorter when the rapid tests were
performed at the point-of-care (24 minutes) than when they were preformed in the laboratory (35 minutes)
(P  0.0001).
These findings show that rapid testing for HIV provides results far sooner than conventional testing in the outpatient
obstetric setting and is acceptable and feasible.
EDITORIAL COMMENT
(Some 100–200 infants in the United States
are infected annually with HIV, as are hundreds
of thousands in less developed countries. If we
are to reduce mother-to-child HIV transmission
to its lowest possible level, we must maximize
the identification of HIV-infected gravidas and
offer them antiretroviral therapy. In select cases,
prelabor, premembrane rupture cesarean deliv-
ery should be offered and performed.
Obviously, to identify HIV infection, one must
test for it, and this testing is greatly facilitated by
an “opt-out” approach, in which the patient is
notified that HIV screening will be performed as
part of her routine prenatal laboratory testing, as
opposed to being performed only after specific
assent for HIV testing is sought and given. The
American College of Obstetricians and Gynecol-
ogists (ACOG), the American Academy of Pedi-
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atrics, and the CDC recommend the opt-out
approach.
In a perfect world, all women would get prenatal
care early in gestation and be tested for HIV infec-
tion. Conventional testing consists of a screening
enzyme-linked immunoabsorbent assay (ELISA)
which, if positive, is followed by a confirmatory
Western blot or an immunoflourescence assay
(IFA). Although conventional testing may be ac-
complished in less than a day, it can take several
days or even more than a week for the testing to
be completed and reported. Early in gestation, this
testing timeframe is acceptable. However, later in
gestation, and in labor, it clearly is not, as the
delay in the availability of the results may preclude
or render less effective mother-to-child HIV trans-
mission prevention interventions.
Fortunately, there are several reliable rapid
HIV tests available, including the OraQuick rapid
HIV antibody test (OraSure Technologies, Beth-
lehem, PA) utilized in the abstracted article of
Tepper et al. This rapid test has a sensitivity of
100% and a specificity of 99.9%, and, in a pre-
vious study, was evaluated by the same inves-
tigators for its utility in diagnosing HIV during
labor. In that study, it performed well, with a
median time from blood collection to patient
notification of 66 minutes, as opposed to 28
hours for enzyme immunoassay (Bulterys M.
JAMA 2004;292:219). Not unexpectedly, in the
Tepper study, rapid testing performed compa-
rably well in obstetric outpatient settings, and
thus can be considered for select women who
are late in gestation and have not yet been
tested for HIV infection.
Based on the performance of the rapid tests,
ACOG recommends rapid HIV testing in labor
for women with undocumented HIV status, and
if the rapid test is positive, that antiretroviral
prophylaxis be initiated (with consent) without
waiting for the results of the confirmatory test
(ACOG Committee Opinion 304, November
2004). The CDC recommends that HIV-infected
women in labor who have not received ante-
partum antiretroviral drugs be given intrave-
nous zidovudine (ZDV) during labor and that
their infants receive 6 weeks of ZDV. In addi-
tion to ZDV, some experts recommend single-
dose intrapartum/newborn neuiropine (available
at: http://AIDSinfo.nih.gov).
Rapid test results should be confirmed by
Western blot or IFA, because even with very
high specificity, if the population tested has a
low prevalence of HIV infection, a substantial
percentage of positive rapid tests will be false
positives. For example, at a prevalence of 1 per
1000, the OraQuick test, which has the lowest
false positive rate of the available tests, has a false
positive rate of 50%. But given that administering
a short course of antiretrovirals to an HIV-negative
parturient has little maternal or perinatal risk, and
can cut the rate of mother-to-child transmission
by one-half to two-thirds, this false positive rate
seems acceptable. Better, clearly, would be de-
finitively knowing all parturients HIV status before
the onset of labor.—DJR)
702 Obstetrical and Gynecological Survey
Evaluation of Universal Antenatal
Screening for Group B Streptococcus
Melissa K. Van Dyke, Christina R. Phares, Ruth Lynfield, Ann R. Thomas,
Kathryn E. Arnold, Allen S. Craig, Janet Mohle-Boetani, Ken Gershman,
William Schaffner, Susan Petit, Shelley M. Zansky, Craig A. Morin,
Nancy L. Spina, Kathryn Wymore, Lee H. Harrison, Kathleen A. Shutt,
Joseph Bareta, Sandra N. Bulens, Elizabeth R. Zell, Anne Schuchat,
and Stephanie J. Schrag
Epidemic Intelligence Service Program, Office of Workforce and Career Development, Centers for Disease Control
and Prevention, Atlanta, GA; Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for
Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; National
Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA;
Minnesota Department of Health, St Paul, MN; Oregon Public Health Division, Portland, OR; Georgia
Department of Human Resources, Division of Public Health, Atlanta, GA; Tennessee Department of Health,
Nashville, TN; California Emerging Infections Program, Oakland, CA; Colorado Department of Public Health and
Environment, Denver, CO; Vanderbilt University School of Medicine, Nashville, TN; Connecticut Department of
Public Health, Hartford, CT; Emerging Infections Program, New York State Department of Health, Albany, NY;
and University of Pittsburgh, Pittsburgh, PA; and New Mexico Department of Health, Santa Fe, NM
N Engl J Med 2009;360:2626–2636
ABSTRACT
In 2002, updated national guidelines recommended universal culture-based antenatal screening of pregnant women
during labor and delivery for detection of colonization with group B streptococcus. Four years later, a population-based
surveillance study reported a 27% decrease in incidence of early-onset neonatal group B streptococcal (GBS) disease.
It is unclear, however, whether there has been an increase in the rate of screening. This retrospective cohort study
examined the medical records of a selected population of more than 800,000 live births to evaluate the implementation
of the 2002 screening and chemoprophylaxis guidelines for the prevention of early onset neonatal GBS disease. It also
assessed missed opportunities for prevention among the women who were not screened. The source of the data was the
Active Bacterial Core Surveillance System, a 10-state network that monitors invasive GBS disease. Between 2003 and
2004, the investigators examined labor and delivery records of a stratified random sample of all live births (newborns
without the disease) and of all cases (newborns with early-onset GBS disease). These data were compared with those
from a similar study evaluating screening practices between 1998 and 1999.
Analysis of abstracted labor and delivery records identified 7437 newborns without GBS disease and 254 newborns with
early-onset GBS disease. Between 1998–1999 and 2003–2004, the rate of screening of women for group B streptococcus
before delivery increased from 48.1% (95% confidence interval, 46.7–49.5) to 85.0% (95% confidence interval, 83.9–86.0),
and the percentage of mothers who received intrapartum antibiotics increased from 26.8% to 31.7%. The observed incidence
of early-onset infections was 0.32 cases per 1000 live births. Among the women positive for group B streptococcus who
delivered at term, the rate of administration of intrapartum antibiotics was 87.0%. Among women with unknown colonization
status who delivered preterm, only 63.4% received intrapartum antibiotics. There was a higher incidence of early-onset GBS
disease in preterm infants than term infants (0.73 vs. 0.26 cases per 1000 live births). Still, only 26% (65/254) of the cases
of early-onset disease were preterm births. Of the infants delivered at term who had early-onset GBS disease, 18.0% (34/189)
were newborns of unscreened women. Term infants born to women who had been both screened and tested negative for group
B streptococcus accounted for 61.4% of the cases of early-onset disease.
These findings suggest that the rapid adoption of recommendations for universal antenatal screening for group B
streptococcus may be responsible for the reported decline in the incidence of early-onset disease in newborn infants 4
years after the updated guidelines were issued.
EDITORIAL COMMENT
(The abstracted study of Van Dyke et al pro-
vides the most contemporary picture of the
state of early onset neonatal group B strepto-
coccal (GBS) disease prevention in the United
States. We perform screening cultures on 85%
of mothers, identify 24% as GBS carriers, and
Preconception and Prenatal Care 703
provide intrapartum prophylaxis to 32%. The
result is an overall rate of early onset neonatal
GBS disease of 0.32 per 1000 live borns. The
rate among term infants is 0.26 per 1000, and
among preterm infants it is 0.73 per 1000.
How, then, are we doing? That is, absent our
fairly intensive screening and treatment efforts,
what would we expect the rate of early onset
neonatal GBS to be? Previously, in a compre-
hensive decision analysis, we estimated that
without maternal GBS screening or intrapartum
antibiotic prophylaxis, the rate of early onset
GBS sepsis would be 2.92 per 1000 births
(Rouse, et al. Obstet Gynecol 1994;83:483). In
the same analysis, we evaluated the current
policy of maternal rectovaginal culture at 35
to 37 weeks, and intrapartum treatment of all
women with positive culture results, GBS bac-
teriuria in the current pregnancy, or delivery of a
previous child with early onset GBS sepsis.
Women in whom a culture result was not avail-
able, and those delivering preterm, or with an
intrapartum temperature of at least 38°C, or
membrane rupture for at least 18 hours would
also receive intrapartum prophylaxis.
We estimated that the current policy would
result in 27% of gravidas being treated with
intrapartum antibiotics (cf the rate of 32% in the
Van Dyke report) and reduce the rate of early
onset GBS sepsis to 0.41 per 1000 births (cf the
rate of 0.32 per 1000 in the Van Dyke report). In
short, we are doing about as well as could be
reasonably predicted. Could we do better?
Probably, but there is 1 fairly fixed impediment
to achieving or even approaching the elimina-
tion of early onset neonatal GBS disease with
our current approach: the imperfect correlation
of maternal antepartum GBS culture results and
intrapartum maternal culture status. Only moth-
ers who are colonized intrapartum are at risk of
giving birth to infants with early onset GBS dis-
ease. Maternal GBS carriage, however, is not
constant, and thus the 35 to 37 week culture
fails to identify all mothers who will be colonized
intrapartum (and, conversely, labels some
women as GBS positive who will not be colo-
nized at the time of delivery).
The best study of the predictive value of the
35 to 37 week culture was by Yancey et al
(Obstet Gynecol 1996;88:811). At a GBS car-
riage rate of 27%, they found a positive predic-
tive value of 87% (i.e., 87% of mothers who are
GBS positive at 36 weeks will be positive at
the time of delivery) and a negative predictive
value of 96% (i.e., 4% of mothers identified as
negative at 36 weeks will actually be colonized
intrapartum). The latter 4%, because they will
not receive GBS prophylaxis, will inevitably give
birth to some infants with early onset GBS
sepsis.
A reliable, highly accurate, and universally
available rapid intrapartum GBS test would ob-
viate the problem of antepartum/intrapartum
culture discrepancies. Such tests exist, but their
wide-scale applicably has not yet been demon-
strated. In the meantime, ensuring that cultures
are obtained, performed, and reported appro-
priately, and that women without culture results
receive prophylaxis if indicated (i.e., for current-
pregnancy GBS bacteriuria, prior affected in-
fant, and those delivering preterm, with fever, or
after prolonged membrane rupture) will help to
ensure that the rate of early onset GBS sepsis is
as low as pragmatically possible.—DJR)
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Mariangela Longini, Giuseppe Buonocore, Maria Elena Venegas,
Hernando Baquero, Gerard H. A. Visser, and Frank Van Bel
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Groningen, Netherlands; Department of Obstetrics and Pediatrics, University of Siena, Siena, Italy;
and Department of Pediatrics, Universidad Del Norte, Barranquilla, Colombia
Pediatrics 2009;124:350–357
ABSTRACT
It has been suggested that early postnatal administration of allopurinol, a xanthine oxidase inhibitor, might reduce
perinatal brain damage because of intrapartum asphyxia. This double-blind randomized pilot study investigated whether
maternal treatment with allopurinol in a population of pregnant women in late labor with signs of fetal hypoxia would
reduce fetal cord serum concentrations of non–protein-bound iron, or other free radicals and S-100, a protein marker of
central nervous system damage. The subjects of the study were 53 women in labor (54 fetuses) at36 weeks’ gestation,
and who had signs of fetal distress (indicated by abnormal or nonreassuring fetal heart rate tracing or fetal scalp pH of
7.20). Each woman was given either a single intravenous dose of allopurinol 500 mg or a saline placebo. The plasma
concentration of allopurinol and its active metabolite oxypurinol were determined from maternal blood and fetal cord
samples obtained at the time of birth.
Median maternal allopurinol/oxypurinol concentrations were in the therapeutic range for xanthine inhibition (2
mg/L for allopurinol and/or 4 mg/L for oxypurinol), and significantly higher compared with fetal arterial cord
concentrations. Therapeutic concentrations were also found in the cord blood of 15 allopurinol-treated newborns.
However, 12 had sub-therapeutic levels. For this reason, 3 treatment groups were created: therapeutic allopurinol (n 
15), sub-therapeutic allopurinol (n  12), and placebo (n  27). The therapeutic allopurinol group had significantly
lower plasma S-100B concentrations compared with the subtherapeutic allopurinol and placebo groups (P  0.01 for
both). Moreover, the concentration of non–protein-bound iron was significantly less in therapeutic allopurinol cord
blood cord samples than that in the subtherapeutic allopurinol and placebo groups (P  0.05 for both).
The investigators believe that this is the first study to demonstrate that maternal allopurinol/oxypurinol can cross the
placenta during fetal hypoxia, and that therapeutic concentrations can reduce serum levels of markers associated with
brain asphyxia. These findings should be confirmed in a larger study using higher doses.
EDITORIAL COMMENT
(In the September 2009 Survey, I commented
on the study of Bhat et al in which asphyxiated
infants with moderate or severe encephalopathy
were randomized to 3 daily infusions of magne-
sium sulfate or to placebo. In that small trial, short-
term outcomes were better in the magnesium
sulfate group. I opined that perhaps it was time
for a trial of magnesium sulfate  whole body
cooling versus whole body cooling alone for
neonatal hypoxic ischemic encephalopathy (Pe-
diatrics 2009;123:e764; SURVEY 2009;64:573).
Try as we might, and perform cesarean delivery
on asmany women as wewill, there will always be
some infants who suffer from hypoxic ischemic
encephalopathy. Neonatal whole body cooling is
a tremendous innovation, but evenwith it, asphyx-
iated infants with moderate or severe encephalop-
athy still face a 24% risk of death, and if they
survive, a 19% risk of cerebral palsy (Shankaran,
et al. NEJM 2005;353:1574). Thus there is a press-
ing need for co-interventions to improve the out-
comes of asphyxiated, encephalopathic infants.
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In 3 small trials that enrolled a total of 114
subjects, allopurinol has been given to newborn
infants with suspected hypoxic-ischemic en-
cephalopathy. The data from these 3 trials have
been aggregated into a meta-analysis in which
allopurinol had no statistically significant effect
on the risk of death (relative risk: 0.92, 95%
confidence interval: 0.59–1.45) or neonatal sei-
zures (relative risk: 0.93, 95% confidence inter-
val: 0.75–1.16). In one trial, neurodevelopment
was assessed among survivors and was not af-
fected by allopurinol. However, even when
aggregated, the studies were statistically under-
powered to detect meaningful differences be-
tween the allopurinol and placebo groups
(Chaudari T, McGuire W. Cochrane Database of
Sys Rev 2008;CD006817).
The rationale for evaluating allopurinol’s po-
tential to improve the outcome of perinatal hy-
poxic ischemic encephalopathy is that it is an
anti-oxidant that may reduce or prevent free
radical damage resultant from reperfusion/re-
oxygenation injury. Free radical generation is
maximal in the first 30 minutes after injury
(McCord JM. NEJM 1985;312:159), and thus the
potential for therapy initiated in the neonatal
period to mitigate hypoxic ischemic brain dam-
age may be limited, especially if not given im-
mediately upon birth.
Torrance et al in the abstracted pilot study,
attempted to answer the question of whether
earlier initiation of allopurinol therapy, ie in the
intrapartum period via maternal administration
to mothers whose fetuses were exhibiting signs
of intrapartum fetal compromise, would be ef-
fective in achieving transfer of allopurinol to the
fetus before birth, and in lowering the neonatal
concentration of a marker of central nervous
system damage, protein S-100B. As to the
former, allopurinol did cross the placenta, and
in approximately half of the perinates who re-
ceived it, achieved serum concentrations that
the authors considered therapeutic on the basis
of previous work (in which the necessary con-
centration of allopurinol and its metabolite
oxipurinol to inhibit xanthine oxidase was deter-
mined). As to the latter, S-100B concentrations
were lower in the sub-group of allopurinol-
exposed perinates who achieved therapeutic
concentrations. This finding, however, is based
on an inappropriate analysis—only the entire
allopurinol group, not a sub-group defined post
hoc, should have been compared with the pla-
cebo group.
Torrance et al are to be congratulated for taking
on the challenge of attempting to identify fetal
compromise, and initiate therapy before deliv-
ery. However, this approach is be-deviled by
our inability to reliably identify fetuses who are in
fact compromised. And if we do identify them,
and delivery is truly urgent, in many cases there
will not be time for the necessary informed con-
sent and study drug administration. For now,
intrapartum therapy to ameliorate the conse-
quences of neonatal hypoxic ischemic enceph-
alopathy is a bridge very far.—DJR)
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Intramuscular Adrenaline Does Not
Reduce the Incidence of Respiratory
Distress and Hypoglycaemia in
Neonates Delivered by Elective
Caesarean Section at Term
P. Pedersen, O. L. Avlund, B. L. Pedersen, and O. Pryds
Department of Neonatology, University Hospital of Copenhagen, Hvidovre, Denmark
Arch Dis Child Fetal Neonatal Ed 2009;94;F164–F167
ABSTRACT
Although delivery of infants by elective cesarean section (CS) before active labor reduces the risk of perinatal
asphyxia and birth injury, it is associated with the occurrence of respiratory distress and hypoglycemia in the newborn
infant.
Previous studies suggest that neonatal respiratory distress and hypoglycemia after elective CS may be secondary to
low catecholamine levels. This randomized, double-blind study investigated whether intramuscular adrenaline might
reduce or eliminate morbidity from neonatal respiratory distress and hypoglycemia in term infants delivered by elective
CS before active labor. The study took place between 2006 and 2007 at a university hospital in Denmark. The newborns
of a total of 270 healthy women with a normal pregnancy at a gestational age of37 completed weeks were randomized
to receive an intramuscular injection of either adrenaline 30 mcg (n  134) or saline (n  135) immediately after birth.
To determine potential changes in heart rate, hemoglobin oxygen saturation, and other potentially serious adverse events
secondary to adrenaline therapy, the first 50 infants were monitored with pulse oximetry. Referral to the neonatal
intensive care unit because of respiratory distress or hypoglycemia was the primary study end point.
Comparison of the incidence of respiratory distress and hypoglycemia in the 2 groups showed no decrease among
infants treated with adrenaline. In fact, these morbidities were higher in the adrenaline group than in the control group
(14% vs. 7%, P  0.048). Monitoring with pulse oximetry during the first 10 minutes of life showed that the heart rate
and hemoglobin oxygen saturation was significantly higher in adrenaline-treated infants compared to the controls (P 
0.001).
These findings show that adrenaline given intramuscularly to newborn infants does not reduce the risk of respiratory
distress or hypoglycemia following elective CS.
EDITORIAL COMMENT
(Again this year, Tita et al have reminded us
that if we are to perform purely elective cesar-
ean delivery and are interested in minimizing
neonatal morbidity, we should wait until 39
completed weeks of gestation. And almost 39
weeks is not the same as 39 weeks, as even
those cesareans performed in the last half of the
38th completed week were associated with sig-
nificantly more neonatal morbidity than those
performed at or beyond 39 weeks (NEJM 2009;
360:111; Survey 2009;64:293).
Certainly, we obstetricians are aware that
elective cesarean delivery before the onset of
labor, especially if performed before 39 weeks’
gestation, increases the risk of neonatal respi-
ratory morbidity. Previously, I reviewed the trial of
Stutchfield et al in which women undergoing elec-
tive cesarean delivery at or beyond 37 weeks’
gestation were randomized to a predelivery
course of betamethasone or to usual treatment
(no betamethasone). Ironically, while that trial
failed to establish that betamethasone was ben-
eficial, it reinforced the wisdom of delaying the
cesarean until 39 completed weeks, as there
was a progressive decline in respiratory morbid-
ity from the 37th to the 38th to the 39th week in
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the control group: 11.4% to 6.2% to 1.5% (BMJ
2005;331:662; Survey 2006;61:157).
In the abstracted study of Pedersen et al, the
potential of another intervention to blunt the risk
of respiratory morbidity after elective cesarean
delivery was evaluated: intramuscular epineph-
rine administered to the neonate immediately
after birth. As described by the authors, the ratio-
nale for testing this intervention was that “adapta-
tion to extra-uterine life is a complex process, and
failure has been partially related to lack of fetal
stress with low levels of circulating catecholamines.”
They note that “during successful transition from
fetal to newborn life an appropriate catecholamine
surge: (1) facilitates ventilation by enhancing water
absorption from alveoli and by promoting surfac-
tant secretion; (2) enhances pulmonary circulation
by raising the systemic blood pressure; and (3)
maintains blood glucose homeostasis by stimulat-
ing hepatic glycogenolysis.”
The rationale for epinephrine, then, seems to
be a good one. However, the epinephrine group
fared worse, with a 14% rate of respiratory dis-
tress or hypoglycemia compared to a 7% rate in
the control group. Moreover, an infant in the
epinephrine group suffered a neonatal stroke
which may or may not have been related to the
epinephrine injection. This trial thus leaves little
reason to suppose that neonatal epinephrine
will ever be a routine, postelective cesarean
delivery intervention, even though the ob-
served differences might have occurred by
chance, leaving open the possibility (albeit a
slim one) that a higher dose of epinephrine
might be effective.
So far, we have no proven, effective therapies
for lowering the risk of neonatal respiratory mor-
bidity after mid to late third trimester, prelabor
cesarean delivery. Maternal corticosteroids such
as betamethasone, the nondefinitive trial of Stutch-
field et al notwithstanding, remain the most
promising intervention, both for their ability to
increase surfactant reduction, and for their po-
tential to enhance alveolar water clearance (Jain
L, et al. Am J Physiol Lung Cell Mol Physiol
2001;280:L646). They need to be tested in a
well-done clinical trial, ideally from 34 to 38
weeks’ gestation a range in which a large
number of prelabor cesareans are currently
being done, respiratory morbidity is apprecia-
ble, and predelivery corticosteroids currently
not standard.—DJR)
Iron Deficiency Anemia, Cigarette
Smoking, and Risk of Abruptio
Placentae
Dodie L. Arnold, Michelle A. Williams, Raymond S. Miller, Chunfang Qiu,
and Tanya K. Sorensen
Department of Epidemiology, University of Washington and Center for Perinatal Studies, Swedish Medical
Center, Seattle, WA
J Obstet Gynaecol Res 2009;35:446–452
ABSTRACT
Some investigators have suggested that there is an association between maternal iron deficiency anemia and the
occurrence of placental abruption. Previous studies investigating this association have had conflicting results or were
compromised by failure to control for confounding variables. This retrospective case-control study investigated the
possible association between maternal iron deficiency and placental abruption in a population of pregnant women from
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a health care network in the Pacific Northwest. Between 1994 and 1998, medical records were used to identify 145
patients with a clinical diagnosis of abruption based on routine clinical examination. A randomly selected sample
of 1710 women without a medical diagnosis of abruption served as the control group. Review of medical records
provided data on maternal sociodemographic characteristics, reproductive and medical history, and history of
smoking during pregnancy. Early pregnancy iron deficiency anemia was defined as first and/or second trimester
hemoglobin 10 g/dL or hematocrit 30%. Adjustment was made by use of logical regression models for
potential confounders including maternal age, gravidity, cigarette smoking during pregnancy, Medicaid payment
status, and pregestational hypertension.
Iron deficiency anemia in early pregnancy occurred in 11.0% of abruptio placentae cases and 3.3% of controls. There was
more than a 3-fold increased risk of placental abruption among women with a history of iron deficiency anemia in early
pregnancy compared to those who did not have iron deficiency anemia (unadjusted odds ratio, 3.60; 95% CI, 2.01–6.04).
Although the risk was reduced following adjustment for confounders, the difference remained statistically significant (adjusted
odds ratio, 2.40; 95% CI, 1.22–4.73). The risk of placental abruption was also increased by maternal smoking during
pregnancy but the abruption iron deficiency anemia association was not modified by maternal smoking status.
The investigators conclude from these findings that iron deficiency anemia in early pregnancy is a risk factor for
placental abruption.
EDITORIAL COMMENT
(This retrospective case control study identi-
fied a significant relationship between iron defi-
ciency anemia and placental abruption; 11% of
women who suffered an abruption had iron de-
ficiency compared to only 3% of controls, and
iron deficiency in early pregnancy increased the
risk of abruption more than 3-fold. Although
smoking during pregnancy was independently
associated with abruption, it did not interact with
or modify the effects of iron deficiency. What is
it about iron deficiency that would predispose to
this adverse advent?
Interestingly, there is data indicating that iron
deficiency strongly influences early placental de-
velopment. Iron deficiency anemia results in re-
duced oxygen carrying capacity and increased
oxidative stress, which prompts adaptive changes
in placental morphology. Studies of placental mor-
phology in anemic versus non anemic pregnancies
have shown that the more severe the anemia as
reflected by serum ferritin levels, the larger the
placenta and the more abundant the placental
vasculature (Hindmarch, et al. Lancet 2000;356:
719). Stereologic studies of placental morphol-
ogy indicate that iron deficiency anemia results
in placental hypertrophy with increased total
capillary volume and surface area (Huang, et al.
Eur J Obstet Gynecol 2001;97:59). These
changes lead to increased gas exchange, which
compensates for the reduced oxygen carrying
capacity of iron deficiency, but the increased
capillarisation likely also creates a more vulner-
able uteroplacental interface.
There is another mechanism by which iron de-
ficiency could predispose to abruption; both
iron deficiency and abruption are associated
with inflammation. Histologic chorioamnionitis,
chorionic vasculitis, and other chronic inflam-
matory lesions of the placenta are signifi-
cantly associated with abruption in both term
and preterm pregnancies (Ananth, et al. Eur J
Obstet Gynecol 2006;128:15; Nath, et al. Am J
Obset Gynecol 2007;197:319.e1). There is evi-
dence that iron deficiency adversely affects
immune function, increases susceptibility to
infection, and makes erthrocytes more vulner-
able to oxidative stress (Allen LH. J Nutrition
2001;131:581s).
World Health Organization (WHO) data indi-
cate that approximately 66% to 80% of the
world’s population are iron deficient (The WHO
Health Report 2002. Reducing Risks, Promoting
Healthy Life. Geneva, WHO, 2002). Two billion
people are actually anemic, including 10% to
15% of the population of industrialized nations;
anemia contributes to 20% of all maternal
deaths worldwide. Hemorrhage is the leading
cause of maternal mortality worldwide, account-
ing for 25% of all deaths (WHO “Make Every
Mother and Child Count,” 2005). Given how
common both iron deficiency and hemorrhage
are, it is not surprising that there is a causative
link between the two. But if vulnerability to ab-
ruption is determined by early placental devel-
opment, as the above data suggest, starting
iron supplementation after pregnancy is rec-
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ognized may be too late. Finding ways to in-
crease the iron intake of reproductive age
women and girls should be a priority for obste-
tricians, and should be addressed at the time of
the annual exam and whenever preconception
counseling is sought.—KDW).
Effects of Female Genital Mutilation on
Birth Outcomes in Switzerland
S. Wuest, L. Raio, D. Wyssmueller, M. D. Mueller, W. Stadlmayr,
D. V. Surbek, and A. Kuhn
Department of Obstetrics and Gynaecology, University of Berne and Inselspital Berne, Berne, Switzerland
BJOG 2009;116:1204–1209
ABSTRACT
Worldwide estimates of the prevalence of female genital mutilation (FGM) indicate that well over 100 million women
in more than 26 countries have undergone this procedure. Illegal in most western countries, FGM is primarily practiced
in sub-Saharan Africa. Many women with FGM have migrated to Western countries where they constitute a significant
proportion of the population. These women have special medical and psychological problems during pregnancy, and do
not readily volunteer that they have undergone the procedure. Most physicians and other health professionals in Western
countries have little knowledge of FGM and its management. There has been concern over reports of increased maternal
and fetal mortality during childbirth among women with FGM. Little data is available on maternal expectations and
wishes concerning antenatal, intrapartum, and postpartum care.
This retrospective case control study evaluated the desires and wishes of women with FGM regarding their external
genitalia following delivery, and as a secondary aim investigated fetal and maternal outcomes among women with FGM
compared to nonmutilated women. The study was conducted between 1999 and 2008 in a teaching hospital setting in
Switzerland. The case subjects were 122 pregnant women volunteers with FGM. Controls were 110 women without
FGM who were matched for maternal age and delivered at the same time. Most patients were from Africa. Defibulation,
a corrective surgical procedure for infibulation, was performed in some patients before or during labor. The primary
study outcome measures were patients’ wishes concerning their FGM management before and during labor, their
satisfaction with the postpartum outcome, and intrapartum and postpartum maternal outcome data including duration of
labor and blood loss as well as fetal outcomes.
When given choices for managing their FGM during pregnancy, 6.5% (8/122) wanted to have antenatal defibulation,
43% (52/122) requested defibulation during labor, 34.4% (42/122) requested defibulation during labor only if deemed
necessary by the medical staff, and 16.5% (20/122) patients were unable to articulate their expectations. No statistical
differences between FGM patients and controls were found for maternal blood loss or duration of labor and fetal
outcomes. Women after FGM did not have a longer duration of labor than the controls. Compared to controls, women
with FGM had significantly more emergency Cesarean sections and third-degree vaginal tears, and significantly fewer
first-degree and second-degree tears. Overall, 76% of patients were very satisfied (53%) or satisfied (23%) with the
management of their FGM.
These findings suggest that appropriate management of women with FGM in pregnancy and its prevention requires
an interdisciplinary team approach with special training in FGM issues.
EDITORIAL COMMENT
(Female genital mutilation (FGM), also improp-
erly called “female circumcision,” has been per-
formed on over 130 million women and girls
worldwide (Guidelines of Women’s Health Care,
3rd edition, ACOG 2007, p243), but is especially
prevalent in sub-Saharan Africa, the Middle
East, and Southeast Asia. It is believed that
FGM is performed for a combination of reasons,
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including attenuation of female sexual desire
and insurance of chastity before marriage, so-
cial or cultural identification, or the belief that it
enhances fertility. Although many western phy-
sicians may never see a case, those who prac-
tice in metropolitan areas that attract African
and Asian immigrants may be called upon to
provide obstetric or gynecologic care to such
women. It is therefore important to understand
the various types of FGM, the anatomic changes
involved, and possible therapeutic options. As
shown in the figure, theWorld Health Organization
recognizes 4 types of FGM: removal of the clitoral
hood or prepuce only, or removal of the prepuce
and partial or complete removal of the clitoris
(Type 1a and 1b); removal of the clitoris and part
or all of the labia minora (Type 2); removing the
clitoris and labia minora, and sewing the labia
majora together over the urethra and most of the
introitis, leaving only a small opening for the pas-
sage of urine and menses (Type 3, also called
infibulation). The WHO also recognizes a fourth
category of mutilation, which includes all other
destructive genital procedures such as pricking,
piercing, cauterizing, scraping, or incising the cli-
toris and labia, and/or traumatizing the vagina with
corrosive substances or or tearing it to induce
scarring that will result in vaginal narrowing (Type
4).
Such procedures are usually performed using
unsterile instruments or even pieces of broken
glass, and the resulting infections and scarring
Fig. Types of female genital mutilation, reprinted from Wikipedia (http://en.wikipedia.org/wiki/Female_genital_cutting).
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can result in anatomic changes so severe the
women often have difficulty urinating, severe
pain with intercourse, menstrual irregularities, ab-
scesses, or even fistulae or incontinence. When
such women become pregnant and present for
delivery, the scar tissue increases the likelihood
of perineal tearing or may even preclude vaginal
delivery.
Obstetrician–gynecologists caring for women
with FGM are in the unique position of possibly
being able to improve the appearance and func-
tion of the scarred perineal structures—if the
woman so desires. The most disturbing data
revealed in Wuest’s study is that at least a third
of infibulated women request defibulation only if
necessary to allow vaginal delivery, although
this may reflect their desire to minimize further
trauma to that area rather than acceptance or
approval of their altered anatomy. For women
who do desire treatment of infibulation, there is
evidence that carbon dioxide laser treatment
may restore the vulvar opening and remove ep-
ithelial inclusion cysts, which are common after
FGM and can become quite enlarged and pain-
ful. Penna and co-workers (Am J Obstet Gynecol
2002;187:1550) described a series of 25 cases of
infibulation, 5 with epidermal inclusion cysts, in
which the vulvar opening was successfully re-
stored with laser and the cyst capsules were
vaporized; the 7 women who were pregnant at
the time were subsequently able to deliver vag-
inally without perineal trauma.
Women who have undergone FGM no doubt
also require psychosocial support and counsel-
ing, although these may be difficult to provide
given the many cultural barriers and the repres-
sive home environments of many affected women.
The first steps toward providing needed care in-
clude recognizing the anatomic changes of FGM,
being sensitive to the cultural issues involved,
being prepared to perform an atraumatic phys-
ical exam, and providing corrective surgery or
referring the patient who desires it to an appro-
priate clinician.—KDW)
Effectiveness of a Multifaceted Strategy
to Improve the Appropriateness of
Cesarean Sections
Andre´s Calvo, Carlos Campillo, Miguel Juan, Catalina Roig,
Juan Carlos Hermoso, and Pedro J. Cabeza
Department of Obstetrics and Gynecology, Hospital of Manacor, Manacor, Mallorca, Spain; Health Services
Evaluation Section, Government of the Balearic Islands, Balearic Islands, Spain; Department of Obstetrics
and Gynecology, Hospital Son Lla`tzer, Mallorca, Balearic Islands, Spain; and Department of Obstetrics and
Gynecology, Hospital de Menorca, Balearic Islands, Spain
Acta Obstet Gynecol 2009;88:842–845
ABSTRACT
Studies evaluating methods to reduce cesarean sections have shown that multifaceted strategies and those
adopted in a single hospital are more effective than centralized strategies and strategies applied in groups of
hospitals. This report discusses the effectiveness of a strategy designed to improve the appropriateness of cesarean
sections in 2 Spanish hospitals. The strategy employed included a protocol with indications for emergency
and prescheduled cesarean sections, evaluating the appropriateness of the protocol, disseminating this evaluation
through continuing education, and introducing measures for improvement. The evaluation was performed in 2
stages: The first stage (preintervention period) evaluated the appropriateness of the cesarean sections performed
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over the 6-month period preceding the adoption of the strategy. In the second stage (postintervention period), the
appropriateness of the cesarean sections performed during the first 6-months of the intervention was
evaluated.
After intervention, there was an increase in overall appropriateness rates for emergency cesarean sections from 68.3 to
84.3% in the first hospital, and from 80.0% to 92.0% in the second hospital. There was a reduction (although statistically
insignificant) in the overall cesarean section rates from 17.5% to 15.8% and from 29.0 to 22.0%, respectively.
The investigators conclude from these findings that implementation of such a multifaceted strategy may be useful to
improve the appropriateness of cesarean sections and possibly lowering their rate.
EDITORIAL COMMENT
(Cesarean delivery rates have been increasing
steadily since 1970, when the rate in the United
States was—it’s hard to believe—only 5.5%
(MMWR 1995;44:303). As summarized by Ecker
and Frigoletto (NEJM 2007;356:885), the in-
crease has been promulgated by many factors.
The advent of widespread fetal heart rate mon-
itoring in the 1970s resulted in an increase in
cesarean delivery performed to protect the fe-
tus; it is disheartening to note that, despite this
intervention, the rates of cerebral palsy, low
birth weight, and perinatal mortality have not
decreased significantly since then (Notzon
F. JAMA 1990;263:3286). Women have gotten
heavier in the last 40 years, resulting in a larger
proportion of parturients who are obese or mor-
bidly obese, and they have also gotten older,
with many women postponing childbearing into
their late 30’s and early 40’s; both these factors
increase the likelihood of cesarean delivery for
cephalopelvic disproportion and dysfunctional
labor. The postponement of pregnancy has also
lead to a higher reliance on reproductive tech-
nology to conceive, and thus a higher rate of
multiple gestations that are delivered by cesar-
ean due to malpresentation and/or prematurity.
The general increase in primary cesareans since
the 1970s has lead, inevitably, to a further bump
in the cesarean rate due to repeat cesareans,
which has been aggravated by the recent wan-
ing of enthusiasm for vaginal birth after cesar-
ean. A relatively new factor is the advent of
“cesarean on maternal request.” Finally, liability
concerns push the cesarean rate even higher,
as more obstetricians fear being sued for “fail-
ure to perform a timely cesarean delivery.”
Many hospitals and national organizations have
weighed in on the runaway cesarean rates. The
World Health Organization (WHO) has stated
that the cesarean rate should be no higher than
15%. Some investigators and physician groups
have created practice guidelines that reduce the
number of cesareans, such as protocols for the
active management of labor (Frigoletto FD,
Lieberman E, Lang JM, et al. NEJM 1995;333:
745) or programs that combine labor manage-
ment protocols with physician feedback and
peer review (Socol ML, Garcia PM, Peaceman
A. Am J Obstet Gynecol 1993;168:1748). It has
been suggested that managed care organiza-
tions could help to reduce the number of cesar-
eans by employing physician—based options
such as peer review, personal performance feed-
back, creation of practice guidelines, and the elim-
ination of incentives for cesarean and creation of
incentives for vaginal birth after cesarean (Maw-
son AR. Am J Manag Care 2002;8:730).
This article by Calvo et al describes a multi-
faceted strategy for improving the “appropriate-
ness” of cesarean deliveries. The investigators
intentionally designed their intervention with this
goal in mind, rather than simply trying to reduce
the cesarean rate, because they believed that if
they succeeded in changing practice through
compliance with specific consensus indications
for cesarean delivery, it might ultimately result in
a more lasting reduction in the number of ce-
sareans performed. They created a list of ap-
proved indications for scheduled cesareans and
for emergency procedures, scheduled a weekly
discussion of all cesareans performed that week,
and did another review every 2 months to spe-
cifically verify that all indications for cesarean
had been appropriate over the previous 2-month
period. They then disseminated the results of
those evaluations to all clinicians and intro-
duced measures for improvement. After the first
12 months, they noted an increase in the appro-
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priateness of cesareans performed and a con-
current reduction in the cesarean rate.
The most interesting part of the study was that
the investigators evaluated the appropriateness
of cesareans for each indication on their list, and
found that the physicians in one or both hospi-
tals were good about complying with some
indications—such as failed induction or arrested
labor—but not so good about complying with
“fetopelvic disproportion” or “risk of fetal distress.”
They noted that some physicians appeared to
interpret fetal heart rate tracings subjectively
rather than use uniform criteria—for which they
proposed no remedy. But for cesareans per-
formed for fetopelvic disproportion, they sug-
gested stratifying the cesarean rates by maternal
BMI and/or maternal age. If the likely rate of ce-
sarean delivery could be predicted by maternal
characteristics, the success or failure of each po-
tential vaginal delivery could be judged by a
patient-specific “expected cesarean rate” rather
than by a single cesarean rate goal for all patients.
The data for such a predictive model are avail-
able. For example, Cnattingius et al (Obstet Gynecol
1998;92:501) used a dataset including more than
92,000 deliveries in Sweden to determine mater-
nal age—and maternal weight—related cesarean
rates. They found that, compared with teenagers,
women age 30 to 34were 2.6 times and those age
35 were 4.4 times more likely to be delivered by
cesarean. Similarly, compared with lean women,
those with a BMI 25 to 29.9 were 1.8 times and
those with a BMI 30 were 2.4 times more likely
to require cesarean delivery. Ecker et al (Am J
Obstet Gynecol 2001;185:883) evaluated all deliv-
eries in one year at Brigham and Women’s Hos-
pital in Boston, and found that the cesarean rate
rose from 11.6% in women younger that 25 years
to 43% for women age 40 or more. Chen and
co-workers (Am J Obstet Gynecol 2004;191:617)
actually developed an easy to use formula—which
they turned into a Web-based calculator—for pre-
dicting the likelihood of cesarean delivery consid-
ering 6 factors: maternal age, maternal height,
initial pregnancy BMI, pregnancy weight gain,
gestational age at delivery, and expected birth
weight.
Many obstetricians are conflicted about the bur-
geoning cesarean rate; on the one hand, they
want to keep the cesarean rate as low as possible,
but on the other, do not want to be driven out of
practice by liability issues. The multifaceted strat-
egy described in this article sounds like a reason-
able approach to the problem.—KDW)
Placental Vascular Pathology Findings
and Pathways to Preterm Delivery
R. Kelly, C. Holzman, P. Senagore, J. Wang, Y. Tian, M. H. Rahbar,
and H. Chung
Department of Epidemiology, College of Human Medicine, Michigan State University, East Lansing, Michigan;
Division of Human Pathology, College of Human Medicine, Michigan State University, East Lansing,
Michigan; Divisions of Epidemiology and Biostatistics, University of Texas School of Public Health at
Houston, Houston, Texas; and Biostatistics/Epidemiology/Research Design (BERD) Core, Center for Clinical
and Translational Sciences, University of Texas Health Science Center at Houston, Houston, Texas
Am J Epidemiol 2009;170:148–158
ABSTRACT
There is limited data on the role of specific maternal placental vascular findings in influencing preterm delivery.
This prospective population-based cohort study examined possible associations between placental vascular
pathology and preterm delivery in a subcohort of pregnant women enrolled in the Pregnancy Outcomes and
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Community Health Study. The study was conducted between 1998 and 2004 in 5 Michigan communities. A total
of 1053 placentas (239 preterm, 814 term) from pregnancies ending in both spontaneous and medically indicated
preterm delivery 37 weeks’ gestation and from women who delivered at term were analyzed. Histologic
evaluation identified 29 placental vascular variables which were grouped into 5 pathology-based groups. Of the 5
groups, 3 were maternal lesions: vascular–obstructive lesions (MV-O); vascular–disturbance of integrity (MV-I);
and vascular–developmental (characterized by abnormal or incomplete remodeling of maternal spiral arteries
(MV-D). The remaining 2 groups were fetal lesions: vascular–obstructive (FV-O) and vascular–disturbance of
integrity (FV-I). Within each group, pathology-based vascular continuous construct scores were obtained by
adding the number of positive findings and calculating a dichotomous variable to approximate the top quintile,
scored as “0” (high), and the bottom 4 quintiles, scored as “1” (not high). Polytomous logistic regression models
were used to adjust for potential confounders.
High scores for each of the five groups were associated with medically indicated preterm delivery at35 weeks, with
unadjusted odds ratios ranging from 2.9 to 6.5. After adjustment for confounders, the association remained statistically
significant. There was a significant association between the risk of spontaneous preterm delivery at 35 to 36 weeks and
a high score for any one of 3 groups: MV-I, MV-D, and FV-I, with adjusted odds ratios ranging from 2.2 to 4.6. A
significant association was found between the risk of spontaneous preterm delivery at 35 weeks and the presence of
2 or more high scores for 3 groups: MV-I, MV-D, and FV-I, with adjusted odds ratios ranging from 4.1 to 7.4. Neither
MV-O nor FV-O was related to spontaneous preterm delivery.
These findings show that a model based on a grouping of pathology-based vascular placental lesions offers insights
into pathways for medically indicated and spontaneous preterm delivery and support the evaluation in future studies of
individual placenta vascular findings within each construct.
EDITORIAL COMMENT
(The American College of Obstetricians and
Gynecology’s (ACOG’s) committee opinion on pla-
cental pathology, originally written in 1993 and
reaffirmed in 2006 (ACOG Committee Opinion #
102, 1993), states that a skilled and systematic
evaluation of the umbilical cord, membranes,
and placenta may yield insight into antepartum
pathophysiology and thus contribute to clinical-
pathologic correlation under certain circumstances,
such as when chorioamnionitis or oligohydram-
nios have been diagnosed clinically and are then
confirmed by placental pathology. However, be-
cause the significance of other placental findings
such as hemorrhagic endovasculitis and chronic
villitis are not well delineated, and pathologists
with the training and experience necessary to per-
form an accurate placental exam are not univer-
sally available, this document did not recommend
submission of every placenta for pathologic
examination. In fact, it has been estimated
that 40% of placental diagnoses made by sur-
gical pathologists who are not placental spe-
cialists are incorrect, of which 90% are errors
of omission—failure to recognize a patholog-
ical lesion—and 10% result from the incorrect
diagnosis of identified lesions (Sun CC. Arch
Pathol Lab Med 2002;126:706). If true, the
lack of widely available expertise in placental
pathology is unfortunate, because this article
by Kelly et al argues convincingly that placen-
tal pathology may reveal important informa-
tion about the development of and damage to
the placenta, and thus provide insight into the
antenatal etiologies of several adverse obstet-
ric outcomes.
Kelly et al devised a sophisticated scheme
for classifying placental lesions, based on
whether the lesions resulted from vascular ob-
struction (infarcts and atherosis), disturbance
of vascular integrity (hemorrhage), or abnor-
mal development (incomplete remodeling of
the spiral arteries), and whether the abnormal-
ity was primarily of maternal or fetal origin.
When this classification system was applied
to 1371 women who had elevated MSAFP
levels and delivered either before 37 weeks or
at term, or had normal MSAFP levels and
delivered at term, they found that 3 specific
lesions were significantly associated with
spontaneous preterm birth before 35 weeks:
disturbance of vascular integrity of maternal
origin, developmental abnormalities of mater-
nal origin, and obstructive vascular lesions of
fetal origin. Further, there were significant in-
teractions between these 3 types of lesions,
such that, after adjusting for maternal charac-
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teristics such as age, race, BMI, parity, and
insurance status, the presence of 2 of the 3
resulted in odds ratios for delivery before 35
weeks ranging from 4.1 (95% CI: 1.2 – 14) to
7.4 (95% CI: 1.3 –42). The presence of any of
the 5 categories of lesions was also signifi-
cantly associated with indicated preterm de-
livery before 35 weeks (OR: 2.9 [1.3–6.4] to 6.5
[2.8–15]), most likely for complications such
as preeclampsia, growth restriction, abruption,
and fetal distress. These results thus provide
confirmation that several adverse pregnancy
outcomes are set in motion weeks to months
before delivery by specific pathological changes in
the placenta.
Although these kinds of pathologic placental
findings may help to deflect blame for obstetric
complications away from intrapartum manage-
ment, which can be important in certain cases,
placental pathology identified after the fact does
not assist antenatal management. However, there
is data indicating that certain placental lesions
are heralded antenatally by abnormal ultra-
sound findings. Infarction and other ischemic
placental lesions are significantly associated
with abnormal Doppler flow velocity waveforms
in the umbilical artery, the fetal middle cerebral
artery, and the ductus venosus; vascular lesions
such as chorioangioma are easily detected
sonographically; areas of intervillous thrombo-
sis or subchorionic fibrin deposits are seen by
ultrasound as “placental lakes” (echolucent ar-
eas with no blood flow within them) or appear as
echolucent cavities within the placental mass;
and areas of previous infarction or fibrin plaques
are often calcified and echodense (Sebire NJ,
Sepulveda W. J Clin Pathol 2008;61:1276). In
fact, prenatal ultrasound has undergone sufficient
advancement that antenatal identification of any of
these defects is often themain reason for submitting
the placenta for pathologic evaluation.
Although routine submission of every pla-
centa for pathologic evaluation may not be
justified, placental pathology is likely to be
helpful in cases in which there has been as
antepartum complication or a poor obstetric
outcome, or there were abnormal ultrasound
findings of the type listed above. Because a
neonatal problem may not be obvious immedi-
ately after delivery, some experts recommend
saving the placenta for 1 week before deciding
to either submit it for evaluation or discard it. If
more obstetricians request placental exami-
nations, perhaps more pathologists will obtain
the training necessary to perform such exams
accurately.—KDW)
Lack of Association Between
Folate-Receptor Autoantibodies and
Neural-Tube Defects
Anne M. Molloy, Edward V. Quadros, Jeffrey M. Sequeira,
James F. Troendle, John M. Scott, Peadar N. Kirke, and James L. Mills
Schools of Medicine and Biochemistry and Immunology, Trinity College, Dublin, Ireland; the Child Health
Epidemiology Unit, Health Research Board, Dublin, Ireland; Departments of Medicine and Cell Biology,
State University of New York–Downstate Medical Center, Brooklyn, NY; and Division of Epidemiology,
Statistics and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Bethesda, MD
N Engl J Med 2009;361:152–160
ABSTRACT
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In a previous pilot study, autoantibodies against folate receptors were found in 75% of serum samples collected
from pregnancies affected by a fetal neural-tube defect, compared to only 10% of samples collected from controls.
Although these findings have been difficult to confirm, primarily due to the lack of suitable assays for
folate-receptor autoantibodies, improved assays are now available. This case-control study investigated whether
the presence of folate-receptor autoantibodies increased the maternal risk of having a pregnancy complicated by
a neural-tube defect. The study subjects included pregnant women in an Irish population with a high prevalence
of neural tube defects. This report is comprised of 2 studies. In study 1, the presence of autoantibodies against
folate-receptors was determined through analysis of stored blood specimens obtained between 1993 and 1994 from 103 case
mothers with a pregnancy complicated by a fetal neural-tube defect, 103 matched-control mothers without normal pregnan-
cies, 58 women with no history of pregnancy, and 36 men. Study 2 used fresh blood samples to rule out the possibility that
any differences found between cases and controls in study 1 could be due to protein degradation occurring during storage of
the frozen specimens. Blood samples in study 2 were collected from 37 case mothers, 22 control mothers, 10 women
who had never been pregnant, and 9 men. Assays for both blocking and binding autoantibodies against folate receptors were
carried out.
In study 1, there was no significant difference between the cases and controls in the frequency of blocking or binding
autoantibodies against folate receptors. Blocking antibodies were present in 17% of case and 13% of control women
(odds ratio [OR], 1.54; 95% confidence interval [CI], 0.70–3.39) and binding autoantibodies were found in 29% of case
and 32% of control women (OR, 0.82; 95% CI, 0.44–1.50). In study 2, similar results were obtained with fresh samples,
indicating that there was little or no degradation of the stored samples.
These findings do not confirm the results of the pilot study and show no association between the presence of
folate-receptor autoantibodies and a history of pregnancy affected by neural-tube defects in an Irish population.
EDITORIAL COMMENT
(The study that prompted this investigation
included only 12 study patients and 20 control
patients, 9 and 2 of whom, respectively, had
antifolate receptor antibodies. The original in-
vestigators did not use commercially available
assays, but rather developed assays in their
own lab; these were fairly complicated, involv-
ing folate receptors isolated from placental tis-
sue and an enzyme linked immunosorbent assay
developed using cow’s milk, making it difficult
for other scientists to confirm the findings. Mal-
loy et al, a group which has contributed greatly
to the literature on neural tube defects (NTDs)
were able to duplicate the assay techniques de-
scribed in the original report, and tested them on
both frozen and fresh serum specimens. They
found that the incidence of folate-receptor
blocking antibodies was similar in stored serum
from case and control mothers (17% vs. 13%),
as was the incidence of folate receptor binding
antibodies (29% vs. 32%).
Was the idea that antifolate receptor autoan-
tibodies could be contributing to the develop-
ment of NTDs far fetched? A wealth of clinical
and metabolic data collected by investigators
around the world supports the link between folic
acid deficiency and NTDs, and folic acid sup-
plementation and a reduction in NTD incidence
(MRC Vitamin Study Research Group. Lancet
1991;338:131; Czeizel AE, Dudas I. N Engl J Med
1992;327:1832); thus folic acid deficiency of some
type is clearly associated with abnormal develop-
ment of the neural tube. Folate occurs naturally in
green and leafy vegetables and other common
foods and in the United States, cereal and grain
has been supplemented with folate since 1998,
yet NTDs continue to occur even in well-nourished
populations. Antifolate receptor autoantibodies
have been identified in other conditions related to
folate deficiency. Raemakers et al (N Engl J Med
2005;352:1985) studied 28 children with cerebral
folate deficiency—a neurologic syndrome caused
by low cerebrospinal levels of 5 methyltetrahy-
drofolate, and marked by irritability, slow head
growth, psychomotor retardation, cerebellar ataxia,
pyramidal signs in the legs, and occasionally
seizures—and identified antifolate receptor au-
toantibodies in 24 (86%) of the affected children
but in none of 28 control subjects with other
neurological diseases. They also determined
that pharmacologic doses of folinic acid (5-
formyltetrahydrofolate) overcame the receptor
problem and induced reversal of symptoms in
some children. Interestingly, noting that the pro-
duction of these autoantibodies began to ap-
pear at 4 to 6 months of life, these investigators
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opined that they were likely induced by soluble
folate-binding proteins in human and bovine
milk.
When the initial report of antifolate receptor
antibodies was published, it aroused great in-
terest. An accompanying editorial by Nicholas
Wald (N Engl J Med 2004;350:101), a leading
authority on NTDs and folate nutriture, opined
that these data suggested a mechanism
through which folate deficiency could cause
NTDs, and thus supported universal folic acid
supplementation. The data presented by Malloy
et al does not change that recommendation.
Even if antifolate receptor antibodies are not
causitive in neural tube defect development,
perhaps because they develop later in life af-
ter exposure to human or bovine milk as sug-
gested above, folic acid supplementation has
been shown in prospective randomized dou-
ble blind trials—the gold standard for research
studies—to reduce the incidence of NTDs. Folic
acid supplementation involves little or no risk and
induces no side effects, thus can be recom-
mended to everyone.—KDW)
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